# MED16

## Overview
MED16 is a gene that encodes the protein mediator complex subunit 16, a critical component of the Mediator complex involved in the regulation of transcription. The Mediator complex serves as a coactivator that facilitates the interaction between RNA polymerase II and various transcription factors, thereby playing a pivotal role in the transcriptional regulation of numerous genes. MED16, specifically, is part of the Tail module of the Mediator complex and is characterized by its bipartite structure, which includes an N-terminal β-propeller domain and a C-terminal α-helical region. This structural configuration allows MED16 to interact with other subunits within the Tail module, such as MED23 and MED24, contributing to the stability and function of the complex (Zhao2021Structure; Verger2019Twenty). MED16 is involved in several biological processes, including the regulation of the antioxidant response through its interaction with NRF2, and it plays a role in cellular protection against oxidative stress (Sekine2016The). Additionally, alterations in MED16 expression have been linked to various cancers, highlighting its significance in both normal cellular function and disease states (Li2022MED16; Gao2020Mediator).

## Structure
MED16, a component of the mammalian Mediator complex, is part of the Tail module and plays a significant role in transcription regulation. The protein has a bipartite structure, consisting of an N-terminal β-propeller domain and a C-terminal α-helical region. The β-propeller forms a large structure that interacts with other subunits in the lower Tail, such as MED23 and MED24, which have homologous structures (Zhao2021Structure). The N-terminal domain of MED16 is involved in forming a complex interface with other Tail subunits, contributing to the stability and function of the Mediator complex (Zhao2021Structure).

The interactions within the Tail module are characterized by a combination of charged, hydrophobic, and cationic-π interactions, which are crucial for the structural integrity of the complex (Zhao2021Structure). MED16, along with MED23 and MED24, forms a submodule within the Tail module in humans, highlighting its role as an interaction hub within the Mediator complex (Verger2019Twenty). The structural conservation of MED16 across species, despite low sequence homology, underscores its essential function in the Mediator complex (Zhao2021Structure).

## Function
MED16, a subunit of the Mediator complex, plays a crucial role in transcriptional regulation by acting as a coactivator for RNA polymerase II-dependent genes. It serves as a bridge between specific transcription factors and RNA polymerase II, facilitating the regulation of gene expression (Gao2020Mediator). In healthy human cells, MED16 is involved in the transcriptional activation of NRF2 target genes, which are essential for the antioxidant response. MED16 interacts with NRF2, a key regulator of this response, and is necessary for the inducible expression of NRF2-activated genes (Sekine2016The). This interaction is crucial for the recruitment of the Mediator complex to NRF2 target gene loci, enabling the phosphorylation of the C-terminal domain of RNA polymerase II, a key step in transcriptional activation (Sekine2016The).

MED16 is also involved in cellular protection against oxidative stress. Its depletion increases susceptibility to oxidative damage, similar to NRF2 knockdown, highlighting its role in mediating the antioxidant response through the KEAP1-NRF2 pathway (Sekine2016The). These functions underscore MED16's importance in maintaining cellular homeostasis and protecting against oxidative stress.

## Clinical Significance
Alterations in the expression of the MED16 gene have been implicated in various cancers, including papillary thyroid cancer (PTC) and estrogen receptor-positive (ER+) breast cancer. In PTC, MED16 is underexpressed compared to normal thyroid tissues, which is associated with increased tumor aggressiveness and resistance to radioiodine (RAI) therapy. This resistance is linked to the activation of the transforming growth factor-β (TGF-β) signaling pathway, promoting epithelial-mesenchymal transition (EMT) and reducing the expression of the sodium/iodide symporter (NIS), crucial for iodine uptake (Gao2020Mediator). MED16 knockdown in PTC cells enhances cell migration and RAI resistance, while its overexpression inhibits these processes (Gao2020Mediator).

In ER+ breast cancer, MED16 expression is higher in cancer tissues compared to normal tissues and is associated with tumor progression and tamoxifen sensitivity. MED16 modulates autophagy through the mTOR signaling pathway, influencing cancer cell survival and proliferation. Overexpression of MED16 enhances tamoxifen sensitivity, while its knockdown reduces sensitivity and increases cancer stem cell characteristics (Li2022MED16). These findings suggest that MED16 plays a significant role in cancer progression and treatment response, highlighting its potential as a therapeutic target.

## Interactions
MED16, a subunit of the Mediator complex, participates in various protein interactions essential for transcriptional regulation. In Drosophila melanogaster, MED16 acts as a coactivator for the differentiation-inducing factor (DIF) activator, directly interacting with the DIF activation domain. This interaction is crucial for DIF-induced transcriptional activation, as demonstrated by GST pull-down assays (Kim2004MED16).

In Arabidopsis, MED16, also known as YID1, interacts with the transcription factors EIN3 and EIL1 through another Mediator subunit, MED25. This interaction is vital for regulating iron homeostasis by maintaining the levels of the FIT protein, a key regulator of iron uptake genes (Yang2014The).

In mammals, MED16 is involved in the KEAP1-NRF2 pathway, where it interacts with NRF2 to facilitate the transcription of antioxidant genes. MED16 directly interacts with the Neh4/5 domain of NRF2, playing a critical role in NRF2-dependent transcriptional activation. This interaction is necessary for the phosphorylation of the RNA polymerase II C-terminal domain, which is essential for the expression of NRF2 target genes (Sekine2016The).


## References


[1. (Yang2014The) Yan Yang, Bin Ou, Jinzhe Zhang, Wen Si, Hongya Gu, Genji Qin, and Li‐Jia Qu. The arabidopsis mediator subunit <scp>med</scp>16 regulates iron homeostasis by associating with <scp>ein</scp>3/<scp>eil</scp>1 through subunit <scp>med</scp>25. The Plant Journal, 77(6):838–851, February 2014. URL: http://dx.doi.org/10.1111/tpj.12440, doi:10.1111/tpj.12440. This article has 110 citations.](https://doi.org/10.1111/tpj.12440)

[2. (Verger2019Twenty) Alexis Verger, Didier Monté, and Vincent Villeret. Twenty years of mediator complex structural studies. Biochemical Society Transactions, 47(1):399–410, February 2019. URL: http://dx.doi.org/10.1042/bst20180608, doi:10.1042/bst20180608. This article has 46 citations and is from a peer-reviewed journal.](https://doi.org/10.1042/bst20180608)

[3. (Li2022MED16) Han Li, Kang Li, Dan Shu, Meiying Shen, Zhaofu Tan, Wenjie Zhang, Dongyao Pu, Wenhao Tan, Zhenrong Tang, Aishun Jin, and Shengchun Liu. Med16 promotes tumour progression and tamoxifen sensitivity by modulating autophagy through the mtor signalling pathway in er-positive breast cancer. Life, 12(10):1461, September 2022. URL: http://dx.doi.org/10.3390/life12101461, doi:10.3390/life12101461. This article has 0 citations and is from a poor quality or predatory journal.](https://doi.org/10.3390/life12101461)

[4. (Gao2020Mediator) Hongwei Gao, Peirong Bai, Lin Xiao, Mengjia Shen, Qiuxiao Yu, Yuanyuan Lei, Wenting Huang, Xiang Lin, Xinyi Zheng, Tao Wei, Yong Jiang, Feng Ye, and Hong Bu. Mediator complex subunit 16 is down-regulated in papillary thyroid cancer, leading to increased transforming growth factor-β signaling and radioiodine resistance. Journal of Biological Chemistry, 295(31):10726–10740, July 2020. URL: http://dx.doi.org/10.1074/jbc.ra119.012404, doi:10.1074/jbc.ra119.012404. This article has 10 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.ra119.012404)

[5. (Sekine2016The) Hiroki Sekine, Keito Okazaki, Nao Ota, Hiroki Shima, Yasutake Katoh, Norio Suzuki, Kazuhiko Igarashi, Mitsuhiro Ito, Hozumi Motohashi, and Masayuki Yamamoto. The mediator subunit med16 transduces nrf2-activating signals into antioxidant gene expression. Molecular and Cellular Biology, 36(3):407–420, February 2016. URL: http://dx.doi.org/10.1128/mcb.00785-15, doi:10.1128/mcb.00785-15. This article has 71 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.00785-15)

[6. (Zhao2021Structure) Haiyan Zhao, Natalie Young, Jens Kalchschmidt, Jenna Lieberman, Laila El Khattabi, Rafael Casellas, and Francisco J. Asturias. Structure of mammalian mediator complex reveals tail module architecture and interaction with a conserved core. Nature Communications, March 2021. URL: http://dx.doi.org/10.1038/s41467-021-21601-w, doi:10.1038/s41467-021-21601-w. This article has 32 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-021-21601-w)

[7. (Kim2004MED16) Tae Whan Kim, Yong-Jae Kwon, Jung Mo Kim, Young-Hwa Song, Se Nyun Kim, and Young-Joon Kim. Med16 and med23 of mediator are coactivators of lipopolysaccharide- and heat-shock-induced transcriptional activators. Proceedings of the National Academy of Sciences, 101(33):12153–12158, August 2004. URL: http://dx.doi.org/10.1073/pnas.0401985101, doi:10.1073/pnas.0401985101. This article has 53 citations.](https://doi.org/10.1073/pnas.0401985101)